The ordinance authorizes a partial settlement of a lawsuit against three major opioid distributors, aiming to secure between $27 million and $50 million in abatement funds over 18 years. This lawsuit alleges that these companies contributed to the opioid crisis in San Francisco by distributing excessive amounts of opioids while ignoring legal obligations to monitor and report suspicious orders.
Ordinance authorizing the partial settlement of the lawsuit filed on behalf of the City and County of San Francisco and the People of the State of California against three large distributors of prescription opioids (AmerisourceBergen Corporation, Cardinal Health, Inc., and McKesson Corporation) for abatement funds in the range of $27 million to $50 million to be paid over 18 years; the lawsuit was filed on December 18, 2018, in the United States District Court for the Northern District of California, Case No. 3:18-cv-7591-CRB-JSC; entitled The City and County of San Francisco and the People of the State of California v. Purdue Pharma L.P., Richard S. Sackler, Jonathan D. Sackler, Mortimer D.A. Sackler, Kathe A. Sackler, Ilene Sackler Lefcourt, Beverly Sackler, Theresa Sackler, David A. Sackler, Trust for the Benefit of Members of the Raymond Sackler Family, Rhodes Pharmaceuticals L.P., Cephalon, Inc., Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA, Inc., Endo International Plc, Endo Health Solutions Inc., Endo Pharmaceuticals Inc., Janssen Pharmaceuticals, Inc., Insys Therapeutics, Inc., Mallinckrodt Plc, Mallinckrodt LLC, Allergan Plc F/K/A Actavis Plc, Watson Pharmaceuticals, Inc. N/K/A Actavis, Inc., Watson Laboratories, Inc., Actavis LLC, Actavis Pharma, Inc. F/K/A/ Watson Pharma, Inc., AmerisourceBergen Corporation, Cardinal Health, Inc., and McKesson Corporation; the lawsuit involves allegations that AmerisourceBergen Corporation, Cardinal Health, Inc., and McKesson Corporation created a public nuisance and violated the Unfair Competition Law and the False Advertising Laws by distributing increasingly large volumes of opioids in and around San Francisco despite knowledge of the growing epidemic caused by opioid misuse, and by failing to prevent and report suspicious opioid orders as required by state and federal law.
How it got here
This legislation originated from a lawsuit filed by the City and County of San Francisco against major opioid distributors to secure abatement funds for the opioid crisis.
The City and County of San Francisco filed a lawsuit in the United States District Court for the Northern District of California against multiple defendants, including AmerisourceBergen Corporation, Cardinal Health, Inc., and McKesson Corporation, alleging public nuisance and violations of competition and advertising laws related to opioid distribution.
The City Attorney prepared an ordinance to authorize the partial settlement of the lawsuit, allowing the City to receive abatement funds estimated between $27 million and $50 million over 18 years.
The Board of Supervisors passed the ordinance on first reading, moving it forward in the legislative process.
The Board of Supervisors finally passed the ordinance, authorizing the settlement of the lawsuit.
The Mayor approved the ordinance, finalizing the settlement process for the lawsuit against the opioid distributors.
Reconstructed from attached documents & the official record
The motion endorses a settlement of a lawsuit against major distributors of prescription opioids, which the City and County of San Francisco filed. It also schedules a public hearing and a closed session for the Board of Supervisors to discuss the litigation with the City Attorney.
The legislation involves a public hearing to discuss proposed ordinances related to a partial settlement of lawsuits against major opioid distributors and manufacturers, seeking abatement funds totaling between $33 million and $61 million over several years. This hearing is scheduled for November 2, 2021, at 3:00 p.m.
This legislation allows the San Francisco Board of Supervisors to hold a closed session to discuss legal advice regarding ongoing lawsuits against major opioid distributors and manufacturers, seeking settlement funds for the city. The lawsuits aim to secure between $27 million to $50 million and $6 million to $11 million in abatement funds to address the opioid crisis over specified timeframes.
The legislation involves a public hearing to discuss proposed ordinances related to a partial settlement of lawsuits against major opioid distributors and manufacturers, seeking abatement funds totaling between $33 million and $61 million over several years. This hearing is scheduled for November 2, 2021, at 3:00 p.m.
This legislation allows the San Francisco Board of Supervisors to hold a closed session to discuss legal advice regarding ongoing lawsuits against major opioid distributors and manufacturers, seeking settlement funds for the city. The lawsuits aim to secure between $27 million to $50 million and $6 million to $11 million in abatement funds to address the opioid crisis over specified timeframes.
The motion endorses a settlement of a lawsuit against major distributors of prescription opioids, which the City and County of San Francisco filed. It also schedules a public hearing and a closed session for the Board of Supervisors to discuss the litigation with the City Attorney.
